Drugs / PD-32766T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07688187 | Jun 2026 → May 2029 expected | clear cell renal carcinoma | PeptiDream Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-32766T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07688187 ↗ |
| Modality | Peptide | “PD-32766T (an Actinium-225 [225Ac] labeled peptide)” NCT07688187 ↗ |
| Route | Intravenous | “administered intravenously” NCT07688187 ↗ |
| Target | CA9 | “PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX” NCT07688187 ↗ |